Pharmaceutical Executive Daily highlights Pfizer's defense of vaccine data integrity, insights on GLP-1 investments, and ...

Enlaza Therapeutics partners with Vertex Pharmaceuticals to advance innovative therapies for autoimmune diseases using ...

Argo Biopharmaceuticals partners with Novartis to advance innovative siRNA therapies for cardiovascular diseases, enhancing ...

Lily and Novo Nordisk are investing in next-gen GLP-1 drugs and other areas, driven by patent cliffs and venture capital ...

Diagnostics 2.0 is a focus on developing evidence very early on.

As the President points out in his post, the COVID vaccines were developed as part of Project Warp Speed (PWS), an initiative launched by President Trump during his first term. While members of his ...

Wayrilz is the first Bruton’s tyrosine kinase inhibitor to be approved for adults with persistent or chronic immune ...

OMass Therapeutics partners with Genentech to advance innovative treatments for inflammatory bowel disease, leveraging their ...

FDA approves Leqembi Iqlik as a weekly subcutaneous injection for Alzheimer's treatment, enhancing patient convenience and ...

Access Infinity launched a new AI-powered price and health technology assessments (HTA) for its market access insights ...

Eli Lilly's oral GLP-1 receptor agonist Orforglipron showed significant weight loss, A1C reduction, and cardiometabolic ...

New indication positions Repatha as an option for high-risk adults with elevated LDL cholesterol and no prior cardiovascular ...